Mainly engaged in the basic research of viral hemorrhagic fever vaccine, diagnostic reagents and related viruses, and the prevention and control of national viral hemorrhagic fever diseases. He has achieved fruitful results in the basic and applied research of hantavirus molecular biology and molecular epidemiology, won the third prize of national scientific and technological progress award and the second prize of the Ministry of Health, established the national monitoring network of epidemic hemorrhagic fever and dengue fever, and completed the monitoring scheme of hemorrhagic fever with renal syndrome and dengue fever and the national diagnostic standard of hemorrhagic fever. Monovalent and bivalent inactivated epidemic hemorrhagic fever vaccines have been successfully developed, and they have obtained new drug certificates and have been commercialized and marketized. The diagnostic kits of IgG,IgM and PCR for epidemic hemorrhagic fever, IgM and PCR for SARS virus were successfully developed. To establish the detection and diagnosis method of viral hemorrhagic fever; Establish important diagnostic techniques for viral hemorrhagic fever including epidemic hemorrhagic fever, dengue fever, Ebola hemorrhagic fever, Marburg hemorrhagic fever and Lassa fever.
Sinnombre virus, the pathogen of Hantavirus lung syndrome, a new infectious disease, was isolated for the first time and the gene rearrangement of Hantavirus was confirmed. It was proved for the first time that Puumala Hantavirus was prevalent in China, and it was found that the non-coding region of Hantavirus gene was related to virus virulence, which played a theoretical guiding role in the development of new vaccines in China. Great achievements have also been made in the research of genetic engineering vaccine of Hantavirus, including the research of genetic engineering vaccine expressing virus-like particles (VLP) of Hantavirus in mammalian cells and the research of live vaccine based on measles virus.
He has presided over more than 1 projects such as 973, 863, National Natural Science Foundation and emerging infectious diseases, and won the third prize of national scientific and technological progress: the second prize of scientific and technological progress of the Ministry of Health and the scientific and technological contribution award of the Army Institute of Infectious Diseases of the US Department of Defense, and obtained 2 new drug certificates and applied for 5 patents. Four results were transferred. Nearly 4 related research papers and works have been published at home and abroad. Train about 2 graduate students.